Neuronetics, Inc. Q2 2026 Earnings Call Summary
Neuronetics reported Q2 2026 progress on its NeuroStar commercial shift to hybrid capital purchase and lease options, with 17% YoY growth at Greenbrook clinics and a 10% utilization increase in active NeuroStar accounts. Management expects choppier H2 2026 revenue, raised full-year gross margin guidance to 48%-50%, and cut operating expense guidance by $5M.
How this was made
The 30-second read
Why it matters
Key trading focus is the guidance mix: management expects choppier 2H 2026 revenue from the model shift, while targeting limited net cash utilization and raising full-year gross margin to 48%-50% based on structural improvements and pricing/mix.
Market read
Traders can update expectations for 2H 2026 revenue timing and margin durability based on the hybrid model transition, cost guidance reduction, and raised gross margin range.
What to watch
The call emphasizes inventory normalization and unused capacity, but traders may need to monitor whether payer authorization improvements sustain and whether the ANT Neuro integration accelerates adoption faster than the commercial model transition disrupts revenue timing.
Background
Neuronetics discussed execution on a hybrid NeuroStar commercialization model, Greenbrook clinic performance, and structural changes including leadership restructuring and a new CFO mandate.
Market effects
Could influence sentiment toward interventional psychiatry delivery models and payer contracting durability, especially around psychedelic therapeutics readiness.
No clear regional spillover described beyond clinic network execution.
Limited, as the disclosed strategy is centered on Greenbrook and NeuroStar commercialization in the US.
Counterpoint
Raised gross margin guidance may rely on mix shift toward capital equipment sales, which could be less repeatable than session revenue if demand normalizes slower than expected.
Key entities
- companyNeuronetics, Inc.
Subject of the earnings call summary, covering NeuroStar commercialization changes, Greenbrook clinic growth, and updated financial guidance.
- product_platformNeuroStar
Interventional psychiatry platform whose revenue reporting and go-to-market model shifted to include capital purchase and lease-finance options.
- business_unitGreenbrook clinics
Primary delivery platform referenced for growth, payer contracting, and capacity utilization ahead of psychedelic therapeutics launches.
- collaboration_partnerANT Neuro
Strategic collaboration to integrate neuronavigation technology into the NeuroStar platform.
